Business Wire

Ecolab Delivers on Commitments to Save Water in Historic AI Era

Share

Water is the world’s most essential resource, and it’s only grown more critical in the age of AI. During this transformative digital revolution, Ecolab, a global sustainability leader that maximizes growth and performance through water solutions and infection prevention services, has continued to meet its goals and work with customers to deliver profitability while advancing optimized water use.

By 2030, it is estimated that AI-related growth will demand additional power equivalent to the annual needs of India1 and as much water to meet the annual drinking water needs of the United States2. As the world navigates the growth of AI and high-tech data centers, there is a unique opportunity to leverage AI to help drive efficiency and innovation in circular water management to improve operational processes and conserve natural resources. Ecolab’s mission to help protect water while driving business growth is more important than ever.

“The rapid acceleration of AI technology is increasing demands on our water and energy resources, yet it also offers unprecedented opportunity to address the water crisis through proprietary connected systems and powerful insights,” said Christophe Beck, chairman and CEO of Ecolab. “By leveraging AI to reduce, reuse and repurpose water throughout business operations, we can continue to win the right way by delivering positive performance for customers while protecting natural resources.”

Ecolab, together with its customers, made significant progress in 2024 to advance water stewardship and help build a more resilient and profitable future. This World Water Day, Ecolab celebrates these achievements in protecting water resources while continuing to grow. Highlights from Ecolab’s 2024 Year in Water include:

  • Water conservation: Ecolab helped customers conserve more than 226 billion gallons of water, equivalent to the annual drinking water needs of more than 781 million people. By 2030, Ecolab aims to help conserve 300 billion gallons of water annually, equivalent to the drinking water needs of 1 billion people.
  • Business growth: Ecolab continued to grow its Global Water business through the acquisition of Barclay Water Management, helping enhance its water safety and digital monitoring solutions.
  • AI-driven solutions: Ecolab collaborated with Digital Realty to deploy an AI-driven water conservation solution in 35 of Digital Realty’s U.S. data centers, aiming to improve water use efficiency and reduce environmental impact.
  • Water treatment partnerships: Nalco Water, Ecolab's water and process management business, partnered with Danieli to enhance industrial water treatment for the metals industry, aiming to improve production processes, reduce carbon and water footprints, and lower costs.
  • Consumer engagement: Ecolab elevated awareness of the importance of water during New York Climate Week with its “Every Drop Counts” exhibit in Bryant Park. It also continued its annual Ecolab Watermark™ Study, which reports on the state of water stewardship around the world.
  • Leading certifications: Ecolab continued pursuing Alliance for Water Stewardship (AWS) certification, bringing its total count of AWS-certified facilities to 12. Ecolab also earned the Water Stewardship Verified (WAVE) certification for its leading water stewardship efforts.
  • Innovative funding: Ecolab participated in a $10 million funding round led by Emerald Technology Ventures to accelerate the global deployment of an innovative PFAS treatment technology, the LEEF System®.
  • Convener of water action: As cofounder of the Water Resilience Coalition (WRC), an industry-driven, CEO-led initiative under the UN Global Compact, Ecolab is committed to addressing the global water crisis. Over the past year, Ecolab helped the WRC make significant strides towards its 2030 roadmap:
    • Investing in Safe Water and Sanitation: Along with Microsoft, Starbucks, Xylem, Reckitt, Gap Inc. and others, Ecolab contributed to the Water & Climate Resilience Fund by WaterEquity. This innovative impact fund has raised more than $100 million, aiming to provide safe water or sanitation access to 15 million people across Africa, Asia and Latin America.
    • Championing California's Water Resilience: As Basin Champion for drought-stricken California, Ecolab convened the second annual forum of the California Water Resilience Initiative (CWRI). This private sector initiative accelerates coordinated, collective action to achieve a water-resilient future for California, aligning with public sector goals.
  • Recognition: Ecolab received public accolades for sustainability, climate and water leadership from CDP, JUST Capital, the Dow Jones and Barron's, among others.
  • Smart Water Navigator: Ecolab continued to offer its informative digital tool to help businesses understand the full value of water in their operations and achieve water goals.

Ecolab’s mission to protect vital resources and deliver business growth is more critical now than ever in the age of AI. By prioritizing smart water management, Ecolab is helping businesses perform while building a more resilient and positive future. Learn more at: https://www.ecolab.com/expertise-and-innovation/water.

About Ecolab

A trusted partner for millions of customers, Ecolab (NYSE:ECL) is a global sustainability leader offering water, hygiene and infection prevention solutions and services that protect people and the resources vital to life. Building on more than a century of innovation, Ecolab has annual sales of $16 billion, employs approximately 48,000 associates and operates in more than 170 countries around the world. The company delivers comprehensive science-based solutions, data-driven insights and world-class service to advance food safety, maintain clean and safe environments, and optimize water and energy use. Ecolab’s innovative solutions improve operational efficiencies and sustainability for customers in the food, healthcare, high tech, life sciences, hospitality and industrial markets. www.ecolab.com

Follow us on LinkedIn @Ecolab, Instagram @Ecolab_Inc and Facebook @Ecolab.

(ECL-C).

1Bloomberg Law, “AI Computing on Pace to Consume More Energy Than India, Arm Says,” April 2024. https://news.bloomberglaw.com/artificial-intelligence/ai-computing-on-pace-to-consume-more-energy-than-india-arm-says.
2Ecolab analysis of data from Lei, N., & Masanet, E. (2022) and Goldman Sachs (2024).

View source version on businesswire.com: https://www.businesswire.com/news/home/20250321820071/en/

Contacts

Kim Del Alcazar
+1-612-483-3698
MediaRelations@Ecolab.com

(c) 2024 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Axelspace: Notice of Signing a Service contract for In-Orbit Demonstration with Pale Blue, Inc.22.12.2025 10:00:00 CET | Press Release

Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” has entered into a service agreement with Pale Blue Inc. (“Pale Blue”), a company that develops, manufactures, and sells thrusters (engines) for small satellites, for an in-orbit demonstration, as detailed below. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219321165/en/ Jun Asakawa, Co-founder & CEO of Pale Blue (left in photo) and Yuya Nakamura, President and CEO of Axelspace Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Under this contract, an in-orbit demonstration of a fast-start Hall thruster developed by Pale Blue is scheduled to be conducted in 2027. Nonetheless, conducting in-orbit demonstrations in a short period of time is known to be a significant challenge due to the in

Axelspace Signing Agreement on a Multi-Launch Arrangement and the Launch of New Satellites with Exolaunch22.12.2025 10:00:00 CET | Press Release

Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” is pleased to announce a multi-launch agreement (MLA) with Exolaunch, a global launch integrator and leader in launch mission management, satellite integration and satellite deployment technologies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219038364/en/ The Multi-Launch Agreement will accelerate the growth of Axelspace. In particular, one satellite scheduled for launch under the new Agreement will be used in the AxelLiner business’s in-orbit demonstration service, “AxelLiner Laboratory”. Exolaunch has already secured launches for eight (8) Axelspace’s satellites on the upcoming missions. Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Nonetheless, conducting in-orbit demonstration

Zambon Biotech Announces First Patient Dosed in Phase 3b ADIP Clinical Study of IPX203 in Parkinson’s Disease22.12.2025 10:00:00 CET | Press Release

Zambon Biotech, a specialized biotech company part of the Zambon group that aims to build a scientifically robust and commercially viable portfolio of innovative patient-oriented drugs through the scouting, acquisition, licensing and development of new molecules, today announced that the first participant with advanced Parkinson’s disease has been enrolled in the European Phase 3b ADIP (IPX203 in Advanced Parkinson’s disease) study, which is planned to evaluate the efficacy and safety of IPX203 versus immediate-release (IR) levodopa/carbidopa (LD/CD) in a regimen which has not yet been the focus of a Phase 3 trial. IPX203 is a novel, oral modified-release formulation of LD/CD designed for the treatment of Parkinson’s disease, the fastest growing neurological condition in the world according to the World Health Organization1. IPX203 contains immediate-release granules and extended-release beads, providing both a rapid onset of action and a longer duration of benefit, sustaining the levo

Pimicotinib Approved as Systemic Treatment in China for Tenosynovial Giant Cell Tumor22.12.2025 09:00:00 CET | Press Release

Merck, a leading science and technology company, announced today that following Priority Review, the China National Medical Products Administration (NMPA) has approved pimicotinib for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection will potentially cause functional limitation or relatively severe morbidity. Pimicotinib, a colony stimulating factor-1 receptor (CSF-1R) inhibitor developed by Abbisko Therapeutics Co., Ltd., Shanghai, China, is the first Chemical Drug Class 1 approved in China for the treatment of TGCT. “We are continuing to deliver on our commitment to improving the lives of patients with rare tumors with this first-in-the-world regulatory approval of pimicotinib,” said Danny Bar-Zohar, CEO Healthcare and Member of the Executive Board of Merck. “This approval is a significant step forward in further strengthening our leadership in rare tumors, while offering patients the opportunity to change the course of

Incyte Japan Announces Approval of Minjuvi ® (tafasitamab) in Combination with Rituximab and Lenalidomide for the Treatment of Relapsed or Refractory Follicular Lymphoma22.12.2025 08:44:00 CET | Press Release

Incyte Biosciences Japan G.K. today announced approval from Japan's Ministry of Health, Labour and Welfare (MHLW) for Minjuvi® (tafasitamab) in combination with rituximab and lenalidomide for adult patients with relapsed or refractory follicular lymphoma (2L+ FL). “Today's approval of Minjuvi in combination with rituximab and lenalidomide marks a significant milestone as the first dual-targeted CD19 and CD20 immunotherapy combination for relapsed or refractory FL in Japan,” said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan. “By improving progression-free survival, Minjuvi offers a chemotherapy-free option for eligible patients with relapsed or refractory disease. This approval underscores our commitment to bridging critical treatment gaps to patients and families affected by this challenging disease in Japan.” The approval is based on the pivotal Phase 3 inMIND trial, which enrolled 654 adult patients, including patients based in Japan. The study demonstrated that Minjuvi

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye